Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial
René Westhovens, Piotr Wiland, Marek Zawadzki, et al.
Lara D. Veeken (2020) Vol. 60, Iss. 5, pp. 2277-2287
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease
Stefan Schreiber, Shomron Ben‐Horin, Jarosław Leszczyszyn, et al.
Gastroenterology (2021) Vol. 160, Iss. 7, pp. 2340-2353
Closed Access | Times Cited: 170
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study
Anthony Buisson, Maria Nachury, Maud Reymond, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 9, pp. 2338-2346.e3
Open Access | Times Cited: 52
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)
Stephen B. Hanauer, Bruce E. Sands, Stefan Schreiber, et al.
Gastroenterology (2024) Vol. 167, Iss. 5, pp. 919-933
Open Access | Times Cited: 12
Biosimilars in IBD: What Every Clinician Needs to Know
Anthony Angyal, Shubha Bhat
Current Gastroenterology Reports (2024) Vol. 26, Iss. 3, pp. 77-85
Closed Access | Times Cited: 8
Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development
John D. Davis, Marçal Bravo Padros, Daniela J. Conrado, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 115, Iss. 3, pp. 422-439
Open Access | Times Cited: 21
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study
Céleste J T van der Togt, Bart J. F. van den Bemt, Daniel Aletaha, et al.
RMD Open (2023) Vol. 9, Iss. 1, pp. e002898-e002898
Open Access | Times Cited: 16
Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease
Xavier Roblin, Stéphane Nancey, Konstantinos Papamichael, et al.
Journal of Crohn s and Colitis (2023) Vol. 18, Iss. 5, pp. 679-685
Closed Access | Times Cited: 16
Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes
Peter C. Taylor, Marco Matucci‐Cerinic, Rieke Alten, et al.
Therapeutic Advances in Musculoskeletal Disease (2022) Vol. 14
Open Access | Times Cited: 24
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
Stefan Schreiber, Shomron Ben‐Horin, Rieke Alten, et al.
Advances in Therapy (2022) Vol. 39, Iss. 6, pp. 2342-2364
Open Access | Times Cited: 22
Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume
Mukesh Desai, Amit Kundu, Michiel Hageman, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 13
Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases
Konstantinos Papamichael, Gabriele Stocco, Ainhoa Ruiz del Agua
Therapeutic Drug Monitoring (2023) Vol. 45, Iss. 5, pp. 579-590
Open Access | Times Cited: 11
Biobetters and biosimilars in Inflammatory Bowel Disease
Jacopo Fanizza, Ilaria Faggiani, Mariangela Allocca, et al.
Best Practice & Research Clinical Gastroenterology (2025), pp. 101992-101992
Closed Access
Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems
Ahmed Aljabri, Ghareb M. Soliman, Yasmin N. Ramadan, et al.
Clinical and Experimental Medicine (2025) Vol. 25, Iss. 1
Open Access
Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit
Rieke Alten, Yoorim An, Dong‐Hyeon Kim, et al.
Clinical Drug Investigation (2022) Vol. 42, Iss. 6, pp. 477-489
Closed Access | Times Cited: 17
Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review
Zhenhua Xu, Jocelyn H. Leu, Yan Xu, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 113, Iss. 5, pp. 1011-1029
Closed Access | Times Cited: 17
Long‐term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH‐LT study
Anthony Buisson, Maria Nachury, Maëva Bazoge, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 59, Iss. 4, pp. 526-534
Closed Access | Times Cited: 9
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Julia Husman, Karin Černá, Katja Matthes, et al.
International Journal of Colorectal Disease (2024) Vol. 39, Iss. 1
Open Access | Times Cited: 3
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters
HoUng Kim, Rieke Alten, Fraser Cummings, et al.
mAbs (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 23
Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis
Roberto Caporali, Yannick Allanore, Rieke Alten, et al.
Expert Review of Clinical Immunology (2020) Vol. 17, Iss. 1, pp. 85-100
Open Access | Times Cited: 23
Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus
Ferdinando D’Amico, Virginia Solitano, Daniel Aletaha, et al.
Autoimmunity Reviews (2021) Vol. 20, Iss. 7, pp. 102849-102849
Open Access | Times Cited: 20
Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease
Philip J Smith, Mathurin Fuméry, Rupert W. Leong, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 9, pp. 1143-1156
Open Access | Times Cited: 7
Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview
Yeo‐Jin Song, Seoung Wan Nam, Chang‐Hee Suh, et al.
Expert Opinion on Drug Metabolism & Toxicology (2023) Vol. 19, Iss. 11, pp. 751-768
Closed Access | Times Cited: 7
To flare or not to flare: patients’ and rheumatologists’ perceptions on the on-flare retreatment strategy of rituximab in rheumatoid arthritis
Delphine Bertrand, Anke Deprez, Michaël Doumen, et al.
Therapeutic Advances in Musculoskeletal Disease (2024) Vol. 16
Open Access | Times Cited: 2
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
Laurent Peyrin‐Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials
Bernard Combe, Yannick Allanore, Rieke Alten, et al.
Arthritis Research & Therapy (2021) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top